UNSPSC 51262408: Amosulalol hydrochloride

This classification denotes an adrenergic antagonist with the molecular formula C18H24N2O5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O4S698PEE, chemically known as benzenesulfonamide, 5-(1-hydroxy-2-((2-(2-methoxyphenoxy)ethyl)amino)ethyl)-2-methyl-, monohydrochloride but more generally known as amosulalol hydrochloride, which bears US NIH Compound Identifier 123707. The base compound, Amosulalol, most often comes in base and hydrochloride forms.

UNSPSC 51262408 Amosulalol hydrochloride is a Commodity code whose nominal pharmaceutical scope shows little alignment with the recent state and local procurement activity tagged under it. The single recent opportunity in the dataset — Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, with response due July 26, 2023 — solicits naloxone and safe drug deactivation systems for community health support, not the beta-blocker medication the code nominally describes. The mismatch suggests either a coding error in the source system or that this Commodity code is not the correct taxonomy placement for active state and local buying in this therapeutic area.

Activity under the code appears limited to the single Seminole County opportunity, which calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with optional one-year renewal, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. The county's e-Procurement Portal accepts electronic bids and requires vendors to meet E-Verify compliance, drug-free workplace certification, and standard commercial insurance. FEMA funding is potential, which introduces federal compliance overlay (Clean Air Act, Federal Water Pollution Control Act). The contract structure is fixed-fee with a three-month probationary termination window. No explicit disadvantaged-enterprise set-asides are noted. Geographic activity appears concentrated in Florida, with no supporting evidence of recent solicitations under this code from other states or issuing bodies. Until additional opportunities surface, this code warrants monitoring only if your firm is positioned in emergency response pharmaceuticals or overdose-reversal procurement channels — the present signal is sparse and misaligned with the code's nominal definition.